Literature DB >> 33526768

Aberrantly high activation of a FoxM1-STMN1 axis contributes to progression and tumorigenesis in FoxM1-driven cancers.

Jun Liu1,2, Jipeng Li3,4, Ke Wang2, Haiming Liu5, Jianyong Sun6, Xinhui Zhao7, Yanping Yu8, Yihuan Qiao9, Ye Wu1, Xiaofang Zhang1, Rui Zhang10,11, Angang Yang12.   

Abstract

Fork-head box protein M1 (FoxM1) is a transcriptional factor which plays critical roles in cancer development and progression. However, the general regulatory mechanism of FoxM1 is still limited. STMN1 is a microtubule-binding protein which can inhibit the assembly of microtubule dimer or promote depolymerization of microtubules. It was reported as a major responsive factor of paclitaxel resistance for clinical chemotherapy of tumor patients. But the function of abnormally high level of STMN1 and its regulation mechanism in cancer cells remain unclear. In this study, we used public database and tissue microarrays to analyze the expression pattern of FoxM1 and STMN1 and found a strong positive correlation between FoxM1 and STMN1 in multiple types of cancer. Lentivirus-mediated FoxM1/STMN1-knockdown cell lines were established to study the function of FoxM1/STMN1 by performing cell viability assay, plate clone formation assay, soft agar assay in vitro and xenograft mouse model in vivo. Our results showed that FoxM1 promotes cell proliferation by upregulating STMN1. Further ChIP assay showed that FoxM1 upregulates STMN1 in a transcriptional level. Prognostic analysis showed that a high level of FoxM1 and STMN1 is related to poor prognosis in solid tumors. Moreover, a high co-expression of FoxM1 and STMN1 has a more significant correlation with poor prognosis. Our findings suggest that a general FoxM1-STMN1 axis contributes to cell proliferation and tumorigenesis in hepatocellular carcinoma, gastric cancer and colorectal cancer. The combination of FoxM1 and STMN1 can be a more precise biomarker for prognostic prediction.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33526768      PMCID: PMC7851151          DOI: 10.1038/s41392-020-00396-0

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN: 2059-3635


  42 in total

1.  Stathmin 1 is a potential novel oncogene in melanoma.

Authors:  J Chen; M Abi-Daoud; A Wang; X Yang; X Zhang; H E Feilotter; V A Tron
Journal:  Oncogene       Date:  2012-06-04       Impact factor: 9.867

Review 2.  Microtubule assembly, organization and dynamics in axons and dendrites.

Authors:  Cecilia Conde; Alfredo Cáceres
Journal:  Nat Rev Neurosci       Date:  2009-05       Impact factor: 34.870

3.  Novel indolyl-chalcones target stathmin to induce cancer cell death.

Authors:  Barbara Wegiel; Yiqiang Wang; Mailin Li; Finith Jernigan; Lijun Sun
Journal:  Cell Cycle       Date:  2016-03-17       Impact factor: 4.534

Review 4.  FOXM1 in Cancer: Interactions and Vulnerabilities.

Authors:  Andrei L Gartel
Journal:  Cancer Res       Date:  2017-06-05       Impact factor: 12.701

5.  Inhibition of stathmin1 accelerates the metastatic process.

Authors:  Karin Williams; Ritwik Ghosh; Premkumar Vummidi Giridhar; Guangyu Gu; Thomas Case; Scott M Belcher; Susan Kasper
Journal:  Cancer Res       Date:  2012-08-21       Impact factor: 12.701

6.  FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells.

Authors:  Yujian Zhang; Nu Zhang; Bingbing Dai; Mingguang Liu; Raymond Sawaya; Keping Xie; Suyun Huang
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

7.  m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program.

Authors:  Sicong Zhang; Boxuan Simen Zhao; Aidong Zhou; Kangyu Lin; Shaoping Zheng; Zhike Lu; Yaohui Chen; Erik P Sulman; Keping Xie; Oliver Bögler; Sadhan Majumder; Chuan He; Suyun Huang
Journal:  Cancer Cell       Date:  2017-03-23       Impact factor: 31.743

8.  FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer.

Authors:  C T Karadedou; A R Gomes; J Chen; M Petkovic; K-K Ho; A K Zwolinska; A Feltes; S Y Wong; K Y K Chan; Y-N Cheung; J W H Tsang; J J Brosens; U-S Khoo; E W-F Lam
Journal:  Oncogene       Date:  2011-08-22       Impact factor: 9.867

9.  FOXM1 confers acquired cisplatin resistance in breast cancer cells.

Authors:  Jimmy M-M Kwok; Barrie Peck; Lara J Monteiro; Helma D C Schwenen; Julie Millour; R Charles Coombes; Stephen S Myatt; Eric W-F Lam
Journal:  Mol Cancer Res       Date:  2010-01-12       Impact factor: 5.852

10.  The stathmin phosphoprotein family: intracellular localization and effects on the microtubule network.

Authors:  O Gavet; S Ozon; V Manceau; S Lawler; P Curmi; A Sobel
Journal:  J Cell Sci       Date:  1998-11       Impact factor: 5.285

View more
  3 in total

1.  STMN1 as a novel prognostic biomarker in HCC correlating with immune infiltrates and methylation.

Authors:  En-di Zhang; Chenxuan Li; Yuan Fang; Na Li; Zhongyun Xiao; Chuhong Chen; Benkai Wei; Hangping Wang; Jincheng Xie; Yinglei Miao; Zhong Zeng; Hanfei Huang
Journal:  World J Surg Oncol       Date:  2022-09-20       Impact factor: 3.253

2.  Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.

Authors:  Dipranjan Laha; Robert R C Grant; Prachi Mishra; Myriem Boufraqech; Min Shen; Ya-Qin Zhang; Matthew D Hall; Martha Quezado; Michelly Sampaio De Melo; Jaydira Del Rivero; Martha Zeiger; Naris Nilubol
Journal:  J Exp Clin Cancer Res       Date:  2022-09-23

3.  TMEM229A suppresses non‑small cell lung cancer progression via inactivating the ERK pathway.

Authors:  Xilin Zhang; Ying He; Yan Jiang; Ying Bao; Qiuqiang Chen; Dong Xie; Huanming Yu; Xiang Wang
Journal:  Oncol Rep       Date:  2021-06-29       Impact factor: 3.906

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.